Low-density lipoprotein-independent effects of statins

被引:199
作者
Davignon, J
Laaksonen, R
机构
[1] Clin Res Inst Montreal, Hyperlipidemia & Atherosclerosis Res Grp, Montreal, PQ H2W 1R7, Canada
[2] Univ Helsinki, Dept Clin Pharmacol, FIN-00014 Helsinki, Finland
关键词
D O I
10.1097/00041433-199912000-00010
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Statins have pleiotropic properties that complement their cholesterol-lowering effects. These properties may partly account for their established benefit in the prevention of coronary artery disease beyond the reduction of LDL-cholesterol levels. The most widely recognized properties are reviewed here. They include: (i) nitric oxide-mediated improvement of endothelial dysfunction and upregulation of endothelin-1 expression; (ii) antioxidant effects; (iii) anti-inflammatory properties; (iv) inhibition of cell proliferation with anticarcinogenic actions in animals; (v) stabilization of atherosclerotic plaques; (vi) anticoagulant effects; and (vii) inhibition of graft rejection after heart and kidney transplantation. As advances are made in our knowledge, new properties are steadily being uncovered. Pleiotropic effects are currently being given consideration when instituting combination therapy for patients at high cardiovascular risk. Some pleiotropic effects are negative, and may account for occasional untoward drug interactions. For many of these new properties, the clinical relevance has not been established. The challenge for the future will be to design and carry out appropriate clinical trials to establish their relative importance in the prevention of coronary artery disease. Curr Opin Lipidol 10:543-559, (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:543 / 559
页数:17
相关论文
共 137 条
  • [121] Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro
    Suzumura, K
    Yasuhara, M
    Tanaka, K
    Suzuki, T
    [J]. BIOCHEMICAL PHARMACOLOGY, 1999, 57 (06) : 697 - 703
  • [122] Lovastatin induces fibroblast apoptosis in vitro and in vivo -: A possible therapy for fibroproliferative disorders
    Tan, A
    Levrey, H
    Dahm, C
    Polunovsky, VA
    Rubins, J
    Bitterman, PB
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (01) : 220 - 227
  • [123] Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats
    Tatsuta, M
    Iishi, H
    Baba, M
    Iseki, K
    Yano, H
    Uehara, H
    Yamamoto, R
    Nakaizumi, A
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (04) : 581 - 587
  • [124] Terada Y, 1998, J AM SOC NEPHROL, V9, P2235
  • [125] BENEFICIAL-EFFECTS OF CHOLESTEROL-LOWERING THERAPY ON THE CORONARY ENDOTHELIUM IN PATIENTS WITH CORONARY-ARTERY DISEASE
    TREASURE, CB
    KLEIN, JL
    WEINTRAUB, WS
    TALLEY, JD
    STILLABOWER, ME
    KOSINSKI, AS
    ZHANG, J
    BOCCUZZI, SJ
    CEDARHOLM, JC
    ALEXANDER, RW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) : 481 - 487
  • [126] Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages
    Umetani, N
    Kanayama, Y
    Okamura, M
    Negoro, N
    Takeda, T
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1996, 1303 (03): : 199 - 206
  • [127] vanBoven AJ, 1997, CIRCULATION, V96, P1060
  • [128] Simvastatin reduces graft vessel disease and mortality after heart transplantation - A four-year randomized trial
    Wenke, K
    Meiser, B
    Thiery, J
    Nagel, D
    vonScheidt, W
    Steinbeck, G
    Seidel, D
    Reichart, B
    [J]. CIRCULATION, 1997, 96 (05) : 1398 - 1402
  • [129] Nitric oxide and hypercholesterolemia: a matter of oxidation and reduction?
    Wever, R
    Stroes, E
    Rabelink, TJ
    [J]. ATHEROSCLEROSIS, 1998, 137 : S51 - S60
  • [130] Are there potential non-lipid-lowering uses of statins?
    Wheeler, DC
    [J]. DRUGS, 1998, 56 (04) : 517 - 522